Rationale for Purchase30 Oct 2013 01:32
I made investments here recently (firstly at 28.3, then at 42), and I don't see the harm in explaining my rationale. The moment of truth will be with us soon. The below is only a personal opinion - DYOR etc.
June 2012 figures revealed Current Assets of £91 million and Total Liabilities of £55 million, implying an NCAV (Net Current Asset Value) of about £36 million.
Fixed Assets of £44 million were intangible except for depreciated PPE of £16.5 million. Additionally, as at June 2012, non-cancellable operating lease obligations due beyond June 2013 were worth £32 million.
Breaking lease obligations would come at a penalty, but my uneducated guess is that in the worst-case scenario, Albemarle could avoid paying £32 million. Penalties and costs of £10 million (I don't know if this is too high or too low, it feels right), combined with liquidation of the £16.5 million of PPE, would produce a net value for Non-Current Assets of about zero.
The company has told us that earnings before extraordinary items are on target this year, which I think limits the potential downside to the company's liquidation value. True, the extraordinary items will have put a dent in the Balance Sheet. There is a risk this deterioration could start to nibble into our NCAV of £36 million, if it's substantially greater than this year's ordinary income. Given that the company is in danger of breaking earnings-related bank covenants, this is a possibility.
But there is also the strong possibility that many of Albemarle's units could be sold as going concerns. Recall that a merger with H&T has been considered for a long time, with talks reported to have been held in 2009 (I am also a shareholder in H&T). EZCORP are also a very obvious candidate to effect a takeover.
What we would really want is for units to be sold as going concerns. We could then attribute positive value to the Non-Current Assets, and should recoup in excess of our £36 million NCAV. It seems to me that £36 million is the lowest residual value which shareholders should hope for in administration, but with good chances for upside.
Absent financial and strategic difficulties, the company should be worth about the same as H&T, let's say 10x forward earnings. Albemarle earned £10-15 million per year recently, and even if this halved to £6-£8 million, a valuation of £60-80 million would be fair.
Now subtract the £35 million financing which management felt they needed to stave off the banks. That gives a value of £25-35 million for the equity rump of an extremely well-capitalised company. But that's less than the NCAV for that equity - little wonder EZCORP said no!
The banks can extract penalties because they have the power to reduce the going concern fair value of the equity down toward value in administration. For this reason, an equity valuation of £80 million is probably aggressive. I